Abbott Lodges New Zemplar Patent Suit Against Hospira

Law360, New York (February 28, 2012, 3:48 PM ET) -- Abbott Laboratories sued generic-drug maker Hospira Inc. on Monday in Delaware federal court, claiming that Hospira infringed its patent by launching plans to produce paricalcitol, which Abbott markets as the kidney disease treatment Zemplar.

Chicago-based Abbott, along with fellow plaintiff the Wisconsin Alumni Research Foundation, claims that Hospira infringed its patent when it lodged a New Drug Application with the U.S. Food and Drug Administration for approval to manufacture and sell paricalcitol injectable drug products before the expiration of Abbott's patent.

At issue is U.S. Patent...
To view the full article, register now.